Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430680 | 0.81 | SMN1; SMN2 (0.39) | HSD17B10GAAPKMALOX15KMT2A | |
| SCHEMBL5478772 | 0.81 | ALDH1A1 (0.46) | KMT2AALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL5481218 | 0.81 | GAA (0.36) | GAAKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL5481198 | 0.80 | TSHR (0.40) | HTTKDM4ETSHR | |
| SCHEMBL12468731 | 0.80 | SMN1; SMN2 (0.41) | HSD17B10GAAKMT2AMEN1ADORA1 | |
| SCHEMBL12468924 | 0.78 | TGM2 (0.47) | LMNA | |
| SCHEMBL3428561 | 0.78 | NPC1 (0.44) | GAASMN1; SMN2NPC1RAB9A | |
| SCHEMBL16935696 | 0.78 | XIAP (0.45) | TAAR1 | |
| SCHEMBL5472897 | 0.78 | L3MBTL1 (0.32) | ALDH1A1L3MBTL1 | |
| SCHEMBL5481561 | 0.78 | ALDH1A1 (0.31) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752609-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-25 | — | — | US | claimed |
| CN-111574575-A | Quinolone derivative containing macrolide group, preparation method and application | 北京理工大学 | 2020-08-25 | — | — | CN | claimed |
| CN-110545817-A | GSK-3 inhibitors | SQUIBB BRISTOL MYERS COMPANY | 2019-12-06 | — | — | CN | claimed |
| US-20190315714-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | claimed |
| EP-3544613-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | claimed |
| EP-2872511-B1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-01-16 | — | — | EP | claimed |
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | claimed |
| WO-2018098412-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | claimed |
| EP-2858983-B1 | TNF-ALPHA MODULATING BENZIMIDAZOLES | UCB BIOPHARMA SPRL (BE) | 2018-04-18 | — | — | EP | claimed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | claimed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | claimed |
| WO-2008010061-A2 | 3-AZABICYCLO [3.1.0] HEXANE VANILLOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-01-24 | — | — | WO | claimed |
| US-6743810-B2 | INTEGRIN INHIBITORS; TUMORS, OSTEOPOROSIS, OSTEOLYTIC DISEASES, SUPPRESSING ANGIOGENESIS, ANTITHROMBOTIC | MERCK PATENT GMBH (DE) | 2004-06-01 | — | — | US | claimed |
| EP-0196005-B1 | PYRIDAZINONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1989-12-20 | — | — | EP | claimed |
| EP-0196005-A1 | Pyridazinones, their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1986-10-01 | — | — | EP | claimed |
| EP-0003771-B1 | CARBOSTYRILE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1982-10-20 | — | — | EP | claimed |
| US-4329347-A | Cardiotonic and antithrombotic sulfur-containing derivatives of carbostyril | BOEHRINGER INGELHEIM GMBH (DE) | 1982-05-11 | — | — | US | claimed |
| US-4225706-A | Polychalcogen ester of cephem compound, process for preparing the same and method for removing the protective group of the same | MEIJI SEIKA KAISHA LTD. (JP) | 1980-09-30 | — | — | US | claimed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-4027027-A | BETA-RECEPTOR-BLOCKERS, HYPOTENSIVES AND VALODILATORS; FOR TREATING ARRYTHMIAS AND ANGINA PECTORIS | CIBA-GEIGY CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315714-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | HSD17B10 207/4885GAA 654/4885PKM 942/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | HSD17B10 2861/4885GAA 1104/4885PKM 465/4885 |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | HSD17B10 2861/4885GAA 1104/4885PKM 465/4885 |
| US-10752609-B2 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | HSD17B10 207/4885GAA 654/4885PKM 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.